Analysis
Local Manufacturing Of 35 APIs Under PLI Scheme Underway As India Seeks Atmanirbharta In Pharma Sector By Reducing Imports From China
Swarajya Staff
Mar 30, 2022, 10:11 AM | Updated 01:51 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Manufacturing of 35 active pharmaceutical ingredients, which have been imported earlier, has started in India under the production linked scheme for the pharmaceuticals sector, Union minister for chemicals and fertilisers Mansukh Mandaviya said on Tuesday (Mar 29).
“Under the production-linked incentive (PLI) scheme, 32 new plants for the production of APIs (Active Pharmaceutical Ingredients) have been set up and production has now started in 35 of the 53 identified APIs," Mandaviya added.
India has a 90 percent dependence on 35 APIs, which used to be imported earlier. However, India has now started manufacturing these APIs under the PLI scheme, the minister stated.
“Under the scheme, the government is providing viability gap funding to reduce dependence on imports.” he further added.
Over 65 percent of India’s API imports come from China.
Last year, the government had announced the Rs 15,000 crore PLI scheme for the pharmaceutical sector and 55 companies, including Sun Pharmaceutical Industries, Aurobindo Pharma, Dr. Reddy's Laboratories, Lupin, Mylan Laboratories, Cipla and Cadila Healthcare, had qualified for incentives under the scheme.
The incentives are to be paid for a maximum period of six years to each qualified company depending upon the threshold investments and sales criteria achieved by the applicant.
The products covered under the scheme include formulations, biopharmaceuticals, active pharmaceutical ingredients, key starting material, drug intermediates, and in-vitro diagnostic medical devices, among others.
According to the government, the objective of the PLI scheme is to enhance India's manufacturing capabilities by increasing investment and production in the pharma sector and contributing to product diversification to high value goods in the pharmaceutical sector.
Also, it aims "to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains".
China is the world's largest producer and exporter of APIs and many of the Indian companies depend on imports of the ingredients to produce formulations.
(With inputs from PTI)
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.